HCW Biologics (HCWB) Q3 2024 earnings summary

Executive summary

• Focused on developing immunotherapies for chronic inflammation, age-related diseases, and autoimmune indications, with a pipeline including proprietary platforms, immune-cell engagers, and multifunctional immunotherapeutic fusions in clinical and preclinical stages.

• Filed IND application for HCW9302 in autoimmune indications, progressing through FDA review.

• Entered a major Settlement Agreement in July 2024, resolving significant legal disputes and clarifying future clinical development strategy.

• Launched a multi-faceted financing plan in Q3 2024, including secured notes, equity financings, licensing transactions, and engaged Maxim Group as exclusive placement agent.

• Entered nonbinding term sheet for licensing a preclinical molecule, with substantial guaranteed payments expected and closing anticipated in Q4 2024.

Financial highlights

• Revenue for Q3 2024 was $426,423, down from $853,102 in Q3 2023; nine-month revenue rose to $2.2M from $1.5M year-over-year, all from Wugen licensing and supply.

• Net loss for Q3 2024 was $3.9M, improved from $4.9M in Q3 2023; nine-month net loss widened to $26.7M from $14.3M year-over-year, driven by legal expenses.

• Cash and cash equivalents at September 30, 2024 were $1.0M or $1.5M, down from $3.6M at year-end 2023.

• Legal expenses surged to $15.8M for the nine months ended September 30, 2024, up from $4.6M in the prior year period, with Q3 2024 legal expenses dropping 54% year-over-year.

• Stockholders’ equity turned negative, from $13.5M at year-end 2023 to a deficit of $10.0M at September 30, 2024.

Outlook and guidance

• Management concluded there is substantial doubt about the ability to continue as a going concern for at least 12 months without additional funding.

• Financing plan includes further secured note issuances, equity raises, and licensing deals; failure to secure capital may require curtailing or ceasing operations.

• Objective to regain Nasdaq listing compliance by December 16, 2024, with possible appeal and extension.

• A nonbinding term sheet for licensing a preclinical molecule is expected to close in Q4 2024, with guaranteed minimum payments.

• Uncertainty regarding FDA feedback and timing for HCW9302 IND application.